Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455878 | 0.85 | MAPT (0.55) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL31208311 | 0.84 | KMT2A (0.43) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL22382337 | 0.84 | KMT2A (0.43) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5469275 | 0.82 | MAPT (0.43) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5455966 | 0.82 | AR (0.44) | MAPT | |
| SCHEMBL6377931 | 0.82 | KMT2A (0.57) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL223250 | 0.81 | ALDH1A1 (0.38) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5467390 | 0.81 | MAPT (0.44) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4859072 | 0.80 | CHEK1 (0.63) | — | |
| SCHEMBL26353145 | 0.80 | ALDH1A1 (0.41) | KMT2ANPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8217044-B2 | Spiroindolinone pyrrolidines | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | disclosed |
| WO-2012038307-A1 | SPIRO SUBSTITUTED PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES USEFUL AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071499-A1 | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones | CHU XIN-JIE (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011134925-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| US-20110269809-A1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN-LA ROCHE INC. | 2011-11-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071499-A1 | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones | IDO1, IDH3A, H1-3 | KMT2A 1955/4885NPC1 3279/4885RAB9A 413/4885 |
| US-20110269809-A1 | SPIROINDOLINONE PYRROLIDINES | RB1, KRAS, PKD1 | KMT2A 1956/4885NPC1 1020/4885RAB9A 122/4885 |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | KMT2A 1856/4885NPC1 1194/4885RAB9A 155/4885 |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | MDM2, TP53, RB1 | KMT2A 1667/4885NPC1 3887/4885RAB9A 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.